Capmatinib

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Congress, Standard of care, Cohort, Endometrial cancer, MCC, Melanoma, Abstract, NSCLC, Docetaxel, RECAP, Capmatinib, Lung cancer, Merkel-cell carcinoma, European Society for Medical Oncology, ESMO, Metastasis, MSI-H, Pharmaceutical industry, Medical imaging, Patient

Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.
  • "We look forward to sharing data from our oncology portfolio with the scientific community at this year’s ESMO Congress,” said Steven Stein, M.D., Chief Medical Officer, Incyte.
  • ET)
    Updated Results from POD1UM-201: A Phase 2 Study of Retifanlimab in Patients with Advanced or Metastatic Merkel Cell Carcinoma (MCC) (Abstract #1146P.
  • ET)
    For full session details and data presentation listings, please see the ESMO Congress 2023 ( https://www.esmo.org/meeting-calendar/esmo-congress-2023/programme ) online program.

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, European Organisation for Research and Treatment of Cancer, Treatment, NSCLC, RTK, AACR, Therapy, Capmatinib, EORTC, Wound healing, National Cancer Institute, American Association for Cancer Research, NCI, Research, Immunomodulation, Poster, HGF, Hepatocyte growth factor, MET, Patient, TKI, Pharmaceutical industry, Cancer

Aberrant MET oncogenic alterations include: MET exon 14 skipping (MET∆ex14) mutations; activating mutations in the kinase domain; MET gene amplification; MET fusions; and MET protein overexpression.

Key Points: 
  • Aberrant MET oncogenic alterations include: MET exon 14 skipping (MET∆ex14) mutations; activating mutations in the kinase domain; MET gene amplification; MET fusions; and MET protein overexpression.
  • Presently, type I c-Met inhibitors such as Capmatinib are used as monotherapies in patients with locally advanced or metastatic NSCLC with MET∆ex14 mutations.
  • However, development of post-treatment resistance to type I c-Met inhibitors occurs clinically, including through acquired mutations in codons D1228 and Y1230.
  • Next generation MET inhibitors are thus needed to treat patients harboring various MET oncogenic alterations beyond MET∆ex14, including post-treatment acquired mutations.

Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Health, Pharmaceutical, Cardiology, Oncology, Workforce, APL, University, Partnership, Arsenic trioxide, International business development, Pharming, Acute promyelocytic leukemia, Personalized medicine, Cancer, Business, CCO, RARA, Acute myeloid leukemia, MDS, AML, Azacitidine, Retirement, Novartis, Patient, CBO, Biology, Bone marrow, Growth, Venetoclax, Pfizer, Clinical pharmacy, Management, Pharmaceutical industry, Capmatinib, Pasireotide, Syros

Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros’ Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023.

Key Points: 
  • Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros’ Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023.
  • Dr. Simonian will remain a member of the Syros Board of Directors following the transition.
  • This includes streamlining our team and, due to capital constraints, stopping further investment in SY-2101 for the foreseeable future.
  • As we look toward near-term data catalysts from SELECT-MDS-1 and SELECT-AML-1, we are planning for our next phase of growth.

Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be Used as a Companion Diagnostic for TABRECTA® (capmatinib)

Retrieved on: 
Friday, July 16, 2021
Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Health sciences, Life sciences, Medicine, Orphan drugs, Medical tests, Biostatistics, Companion diagnostic, Medical diagnosis, Novartis, Capmatinib, Foundation Medicine, Medication, FoundationOne Liquid CDx, Foundation Medicine, FOUNDATIONONE LIQUID CDX, FOUNDATION MEDICINE

[2] Today's approval adds to the number of therapies for which both of Foundation Medicines FDA-approved comprehensive genomic tests are listed as companion diagnostics.

Key Points: 
  • [2] Today's approval adds to the number of therapies for which both of Foundation Medicines FDA-approved comprehensive genomic tests are listed as companion diagnostics.
  • FoundationOneCDx, Foundation Medicines tissue test, was approved as a companion diagnostic for TABRECTA in May 2020.
  • TABRECTA is the second therapy for which both of Foundation Medicines FDA-approved tests, FoundationOne CDx and FoundationOne Liquid CDx, are listed as companion diagnostics.
  • Foundation Medicine and FoundationOne are registered trademarks of Foundation Medicine, Inc.
    TABRECTA is a trademark of Novartis.

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Retrieved on: 
Friday, June 4, 2021
Health sciences, Health, Breakthrough therapy, Orphan drugs, Medical research, Cancer research, Response Evaluation Criteria in Solid Tumors, Lung cancer, Clinical endpoint, Survival rate, Non-small-cell lung carcinoma, Capmatinib

"The impressive overall survival outcome and confirmed outstanding response in the first-line setting will help oncologists decide upon a therapeutic option for patients."

Key Points: 
  • "The impressive overall survival outcome and confirmed outstanding response in the first-line setting will help oncologists decide upon a therapeutic option for patients."
  • "The introduction of Tabrecta a year ago dramatically changed the treatment landscape for patients with METex14 NSCLC.
  • The primary endpoint was overall response rate (ORR) based on the Blinded Independent Review Committee (BIRC) assessment per RECIST v1.1.
  • The effectiveness of TABRECTA in these patients is based on a study that measured 2 types of response to treatment (response rate and duration of response).

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Antineoplastic drugs, Health care, Breakthrough therapy, Orphan drugs, American Society of Clinical Oncology, Incyte, Asco, Capmatinib, Non-small-cell lung carcinoma, Drugs, Health

b'Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.\n\xe2\x80\x9cWe look forward to presenting data from across Incyte\xe2\x80\x99s oncology portfolio and partner programs at this year\xe2\x80\x99s ASCO Annual Meeting,\xe2\x80\x9d said Steven Stein, M.D., Chief Medical Officer, Incyte.

Key Points: 
  • b'Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.\n\xe2\x80\x9cWe look forward to presenting data from across Incyte\xe2\x80\x99s oncology portfolio and partner programs at this year\xe2\x80\x99s ASCO Annual Meeting,\xe2\x80\x9d said Steven Stein, M.D., Chief Medical Officer, Incyte.
  • )\nCapmatinib in MET Exon 14-Mutated, Advanced NSCLC: Updated Results from the GEOMETRY Mono-1 Study3(Abstract #9020.
  • )\nCapmatinib Efficacy in Patients with NSCLC Identified as METex14 Using an NGS-Based Liquid Biopsy Assay: Results from the GEOMETRY Mono-1 Study3(Abstract #9111.
  • )\nFor full session details and data presentation listings, please see the ASCO21 online program at https://meetinglibrary.asco.org .

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug

Retrieved on: 
Wednesday, April 14, 2021
Research, Infectious diseases, Biotechnology, Health, University, Pharmaceutical, Science, Education, Oncology, Cyclica, Larentiinae, Capmatinib, Drugs, Clinical medicine

b"Cyclica , the partner of choice for data driven drug discovery, in connection with leading Canadian research institutions, has predicted a repurposing drug, capmatinib, with evidence that it attenuates the impact of coronavirus.

Key Points: 
  • b"Cyclica , the partner of choice for data driven drug discovery, in connection with leading Canadian research institutions, has predicted a repurposing drug, capmatinib, with evidence that it attenuates the impact of coronavirus.
  • \xe2\x80\x9cOur business model has always relied on tight collaboration with partner institutions, accelerated by our AI drug discovery platform.
  • To learn more about Cyclica\xe2\x80\x99s drug discovery platform, please visit https://www.cyclicarx.com/ .\nFrom Molecule to medicine, Cyclica embraces the complexity of disease.
  • To learn more about Cyclica and how we partner, please visit www.cyclicarx.com\nRyerson University is Canada's leader in innovative, career-oriented education.

Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

Retrieved on: 
Wednesday, September 2, 2020
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Life sciences, Health, Industries, Breakthrough therapy, Incyte, Protein kinase inhibitor, Antineoplastic drugs, Orphan drugs, Lung cancer, Novartis, Non-small-cell lung carcinoma, Capmatinib, Tabrecta, Incyte

The GEOMETRY mono-1 study results published in The New England Journal of Medicine further highlight the clinical benefit that Tabrecta can provide to patients with metastatic METex14 NSCLC, said Steven Stein, M.D., Chief Medical Officer, Incyte.

Key Points: 
  • The GEOMETRY mono-1 study results published in The New England Journal of Medicine further highlight the clinical benefit that Tabrecta can provide to patients with metastatic METex14 NSCLC, said Steven Stein, M.D., Chief Medical Officer, Incyte.
  • Incyte is eligible for a total of over $500 million in milestones as well as royalties of between 12-14% on global net sales by Novartis.
  • Tabrecta (capmatinib) is a kinase inhibitor that targets MET discovered by Incyte and licensed to Novartis in 2009.
  • Under the terms of the Agreement, Incyte granted Novartis exclusive worldwide development and commercialization rights to capmatinib and certain back-up compounds in all indications.

Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, February 11, 2020
Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Cancer, Clinical medicine, Medicine, Non-small-cell lung carcinoma, Targeted therapy, Lung cancer, Small-cell carcinoma, Treatment of lung cancer, MEK inhibitor, GEOMETRY mono-1, Capmatinib, Incyte

If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis2,3.

Key Points: 
  • If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis2,3.
  • We are pleased the FDA has accepted the NDA for capmatinib for Priority Review a critical step toward providing the first METex14 mutation targeted therapy to this subset of lung cancer patients.
  • This designation shortens the FDA review period following the acceptance of the NDA to six months compared to 10 months for Standard Review.
  • Capmatinib (INC280) in METex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the Phase 2 GEOMETRY mono-1 study.